The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Atyr Pharma Inc. Common Stock 002120103 580 130,572 SH   SOLE   130,572 0 0
Dare Bioscience, Inc. Common Stock 23666P101 323 326,243 SH   SOLE   326,243 0 0
Fate Therapeutics, Inc. Common Stock 31189P102 39,106 1,139,783 SH   SOLE   1,139,783 0 0
Genocea Biosciences, Inc. Common Stock 372427401 566 246,078 SH   SOLE   246,078 0 0
Lyra Therapeutics, Inc. Common Stock 55234L105 12,484 1,100,852 SH   SOLE   1,100,852 0 0
Neuronetics, Inc. Common Stock 64131A105 1,414 732,583 SH   SOLE   732,583 0 0
Phreesia, Inc. Common Stock 71948P106 62,615 2,214,092 SH   SOLE   2,214,092 0 0
Pulmatrix, Inc. Common Stock 74584P202 618 359,439 SH   SOLE   359,439 0 0
Selecta Biosciences, Inc. Common Stock 816212104 7,877 2,773,479 SH   SOLE   2,773,479 0 0
x4 Pharmaceuticals Inc. Common Stock 98420x103 2,903 311,492 SH   SOLE   311,492 0 0